As of close of business last night, Maravai LifeSciences Holdings Inc’s stock clocked out at $8.14, up 0.37% from its previous closing price of $8.11. On the day, 1568890 shares were traded.
Ratios:
To gain a deeper understanding of MRVI’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.75. For the most recent quarter (mrq), Quick Ratio is recorded 7.41 and its Current Ratio is at 8.00. In the meantime, Its Debt-to-Equity ratio is 1.47 whereas as Long-Term Debt/Eq ratio is at 1.44.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on April 10, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On December 12, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also lowered its target price recommendation from $10 to $8.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.73 while its Price-to-Book (P/B) ratio in mrq is 2.58.
Stock Price History:
Over the past 52 weeks, MRVI has reached a high of $16.62, while it has fallen to a 52-week low of $4.52.
Shares Statistics:
A total of 132.23M shares are outstanding, with a floating share count of 106.81M. Insiders hold about 19.27% of the company’s shares, while institutions hold 85.97% stake in the company.
Earnings Estimates
As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.03, while EPS last year was $0.03. The consensus estimate for the next quarter is -$0.01, with high estimates of $0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.03 and -$0.06 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is $0.05, with 12 analysts recommending between $0.11 and -$0.01.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $60.55M. It ranges from a high estimate of $62.2M to a low estimate of $58.7M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $79.03M, an estimated decrease of -23.40% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $66.81M, a decrease of -3.10% over than the figure of -$23.40% in the same quarter last year. There is a high estimate of $69M for the next quarter, whereas the lowest estimate is $63M.
A total of 12 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $275.3M, while the lowest revenue estimate was $265M, resulting in an average revenue estimate of $271.81M. In the same quarter a year ago, actual revenue was $288.94M, down -5.90% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $298.37M in the next fiscal year. The high estimate is $323.39M and the low estimate is $284.72M. The average revenue growth estimate for next year is up 9.80% from the average revenue estimate for this year.
